Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2016. The document serves as a transaction notification regarding share allocation arrangements for Independent Non-Executive Directors for the service period of July 1, 2016, to September 30, 2016.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific director share transactions.
| Instrument | Price | Total Volume (Shares/ADSs) |
|---|---|---|
| Ordinary Shares (GBP) | £16.43 | 5,486.224 |
| American Depositary Shares (USD) | $40.70 | 1,585.898 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of notional shares by directors as compensation.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of director shareholdings.
Investor Verification Checklist
- Verify the total number of notional shares acquired by directors against the company's share allocation policy.
- Confirm the transaction date (October 26, 2016) aligns with the service period (July 1 – September 30, 2016).
- Note that this filing does not reflect the company's Q3 or full-year 2016 financial performance.